302 related articles for article (PubMed ID: 18671165)
1. Development of new antileishmanial drugs--current knowledge and future prospects.
Le Pape P
J Enzyme Inhib Med Chem; 2008 Oct; 23(5):708-18. PubMed ID: 18671165
[TBL] [Abstract][Full Text] [Related]
2. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of leishmaniasis: past, present and future.
Mishra J; Saxena A; Singh S
Curr Med Chem; 2007; 14(10):1153-69. PubMed ID: 17456028
[TBL] [Abstract][Full Text] [Related]
4. Marine Algae as Source of Novel Antileishmanial Drugs: A Review.
Tchokouaha Yamthe LR; Appiah-Opong R; Tsouh Fokou PV; Tsabang N; Fekam Boyom F; Nyarko AK; Wilson MD
Mar Drugs; 2017 Oct; 15(11):. PubMed ID: 29109372
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
6. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
[TBL] [Abstract][Full Text] [Related]
7. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
Palumbo E
Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
[TBL] [Abstract][Full Text] [Related]
8. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
9. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
10. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
11. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
12. An update on small molecule strategies targeting leishmaniasis.
Kapil S; Singh PK; Silakari O
Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
[TBL] [Abstract][Full Text] [Related]
13. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Vanaerschot M; Dumetz F; Roy S; Ponte-Sucre A; Arevalo J; Dujardin JC
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):937-46. PubMed ID: 24802998
[TBL] [Abstract][Full Text] [Related]
14. Leishmaniasis.
Herwaldt BL
Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
[TBL] [Abstract][Full Text] [Related]
15. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
[TBL] [Abstract][Full Text] [Related]
16. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives.
Fuertes MA; Nguewa PA; Castilla J; Alonso C; Pérez JM
Curr Med Chem; 2008; 15(5):433-9. PubMed ID: 18288998
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis in children: a review.
Palumbo E
Minerva Pediatr; 2010 Aug; 62(4):389-95. PubMed ID: 20940672
[TBL] [Abstract][Full Text] [Related]
19. Natural product based leads to fight against leishmaniasis.
Singh N; Mishra BB; Bajpai S; Singh RK; Tiwari VK
Bioorg Med Chem; 2014 Jan; 22(1):18-45. PubMed ID: 24355247
[TBL] [Abstract][Full Text] [Related]
20. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
